About Beactica
Beactica is a Healthcare company based in Uppsala (Sweden) founded in 2006. It develops small molecule drugs for oncology. Beactica offers products and services including Eclipsorâ„¢ Synthetic Lethality Platform. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Beactica Therapeutics AB.
Company details
Beatica develops small molecule drug discovery platforms. Its proprietary platform is based on surface plasmon resonance and is designed to predict molecule - target interaction, especially when protein crystallization is not possible. The company offers lead optimization and other drug discovery services to pharma companies and research organizations. In addition, Beatica is planning to develop an internal pipeline of its own molecules as well.
- Headquarters Uppsala, Sweden
- SectorsHealthcare
- Website beactica.com
- Social LinkedIn X
- Legal Name Beactica Therapeutics Ab
- Latest Funding Round$2.96M (USD), Grant
Feb 2026
- InvestorsEuropean Union
& 7 more
Products & Services of Beactica
Beactica offers a comprehensive portfolio of products and services, including Eclipsor™ Synthetic Lethality Platform.
Platform for identifying synthetic lethality in targeted cancer therapies
Funding Insights of Beactica
- Total Rounds 12
- Last Round Grant — $2.96M
- Investors Count 8
Latest 10 of 12 funding rounds of Beactica with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $2.96M | Grant | – | – | |
| Dec 2019 | $326,253 | Grant | – | – | |
| Jun 2019 | Series A | – | Unionen, Almi Invest | ||
| Sep 2018 | $58,006 | Grant | – | – | |
| Aug 2018 | Series A | – | Unionen, Almi Invest | – | |
| Apr 2018 | $61,568 | Grant | – | – | |
| Mar 2016 | $286,650 | Grant | – | – | |
| Dec 2014 | Seed | – | – | ||
| Nov 2014 | $405,000 | Grant | – | – | |
| Feb 2011 | $954,000 | Grant | – | – | – |
8 investors in total: 8 institutional.
Investors in Beactica
Beactica has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Vinnova and Uppsala University.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by corporate-backed Almi Invest. | almi.se/Almi-Invest/ | Lund, Sweden | ||
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Venture capital funding is provided to Swedish companies across sectors. | 2001 | vinnova.se | Stockholm, Sweden | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Online customer service courses are delivered via a learning platform. | 2008 | unionen.se | Stockholm, Sweden | |
University offering multiple courses and degrees across diversified streams | 1477 | uu.se | Uppsala, Sweden | |
| ec.europa.eu |
Investor details for Beactica
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Beactica
8 people are tracked at Beactica (4 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Per Källblad | Co-Founder and CEO | Leadership |
Johan Winquist | Head Of Operations | Leadership |
Konrad Koehler | Head of Discovery | Leadership |
Peter Brandt | Head Of Chemistry | Leadership |
Wei Berts | Principal Scientist | Team |
Matthis Geitmann | Principal Scientist | Team |
Gun Stenberg | senior scientist | Team |
Rajiv Sawant | Senior Research Scientist | Team |
Complete people profiles for Beactica
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Beactica
3 dated milestones of Beactica across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Beactica is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $3.0M.
Web traffic of Beactica
The website of Beactica (beactica.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 28.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Beactica
Complete news archive for Beactica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beactica
Beactica was founded in 2006 and raised its 1st funding round 3 years after it was founded.
Beactica is headquartered in Uppsala, Sweden. It is registered at Uppsala, Uppsala County, Sweden.
Beatica develops small molecule drug discovery platforms. Its proprietary platform is based on surface plasmon resonance and is designed to predict molecule - target interaction, especially when protein crystallization is not possible. The company offers lead optimization and other drug discovery services to pharma companies and research organizations. In addition, Beatica is planning to develop an internal pipeline of its own molecules as well.
Beactica offers Eclipsorâ„¢ Synthetic Lethality Platform.
Beactica has 8 investors. Key investors include European Union, Vinnova, Uppsala University, Unionen, and Almi Invest.
Beactica operates through Beactica Therapeutics Ab.